ARA-290 Research Guide

Full name: Cibinetide (ARA-290)

An 11-amino-acid peptide derived from erythropoietin (EPO) that targets the innate repair receptor without the blood-cell-stimulating (erythropoietic) effects of EPO. Investigated for neuropathic pain and inflammatory conditions such as sarcoidosis-associated small fiber neuropathy.

How ARA-290 Works

Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation.

Dosing Protocol

• Typical dose: 1-4 mg per dose
• Frequency: Daily during a course
• Duration: 4 weeks (typical study course)
• Route: Subcutaneous injection

Reported Benefits

• Reduces neuropathic pain
• Anti-inflammatory tissue protection
• Supports small-fiber nerve repair
• No increase in red blood cell mass (unlike EPO)

Potential Side Effects

• Generally well tolerated in trials
• Mild injection site reactions
• Headache (uncommon)

Research Citations

1. ARA-290 in sarcoidosis-related small fiber neuropathy (2017) - Reduced neuropathic pain and improved corneal nerve fiber measures versus placebo.
2. Cibinetide and innate repair receptor signaling (2016) - Demonstrated tissue-protective, anti-inflammatory effects without erythropoiesis.

Related Pain & Inflammation Compounds

• Low-Dose Naltrexone (LDN) - Full Profile
• PEA - Full Profile
• Diclofenac Topical - Full Profile
• Pentosan (Joint Pain) - Full Profile
• Boswellia (AKBA) - Full Profile
• Cartalax - Full Profile

View full ARA-290 profile with 3D molecule viewer →